This article is more than 5 years old. Information may no longer be current.
Advaxis, Bristol-Myers Squibb to explore treatment option for metastatic cervical cancer
Click Here to Manage Email Alerts
Advaxis and Bristol-Myers Squibb entered into a clinical collaboration to investigate a potential combination treatment for women with metastatic cervical cancer.
The study will evaluate the combination of axalimogene filolisbac (ADXS-DUAL, Advaxis), an investigational immunotherapy that targets HPV–associated cancers, plus nivolumab — a PD-1 immune checkpoint inhibitor — in women with persistent, recurrent or metastatic carcinoma of the cervix who failed at least one prior line of systemic chemotherapy.
The study is expected to begin by the end of this year.
“Combining immunotherapy agents is at the core of Bristol-Myers Squibb’s strategy, as it brings the opportunity to improve antitumor efficacy,” Fouad Namouni, MD, head of oncology development at Bristol-Myers Squibb, said in a company-issued press release. “We are excited to work with Advaxis to explore the potential of Opdivo and ADXS-DUAL to provide a potential new option for metastatic cervical cancer patients where there is a high unmet need.”
ADXS-DUAL is under evaluation as monotherapy for patients with high-risk, locally advanced cervical cancer in the global phase 3 AIM2CERV trial.
“The additional HPV antigens have the potential to provide coverage against numerous HPV types in cervical cancer and other HPV–associated cancers,” Daniel J. O’Connor, president and CEO of Advaxis, said in the release. “By studying the combination of Opdivo and ADXS-DUAL, we hope to bring a new option to metastatic cervical cancer patients with persistent, recurrent or metastatic disease. We are looking forward to working with Bristol-Myers Squibb to explore the potential of this combination.”